GlassScriptPhysician profile
Charles Delacuadra
NPI 1972759678
$1,913.46
in general payments reported to CMS, 2019-2025
23 companies · $793 in 2025
The $793 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2022: $25.81 · 2023: $208 · 2024: $737 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.49 | 2023-2025 | Qulipta |
| Novo Nordisk INC | $241.76 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $234.76 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $150.56 | 2025 | Rexulti |
| Gilead Sciences, INC. | $124.97 | 2019 | |
| Lundbeck LLC | $103.75 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.67 | 2023-2025 | Xifaxan |
| Corcept Therapeutics | $92.49 | 2024 | Korlym |
| Pfizer INC. | $91.99 | 2022-2024 | |
| Exact Sciences Corporation | $86.91 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shield Therapeutics INC | $76.26 | 2023-2024 | Accrufer |
| Verity Pharmaceuticals INC. | $60.43 | 2025 | Tlando |
| Merck Sharp & Dohme LLC | $51.35 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $46.60 | 2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $32.92 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $25.50 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.18 | 2019 | |
| Ardelyx, INC. | $22.89 | 2024 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.83 | 2025 | Caplyta |
| Amgen INC. | $21.22 | 2024 | Evenity |
| Becton, Dickinson and Company | $18.97 | 2025 | Bd Veritor Plus Analyzer |
| Dexcom, INC. | $16.38 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Delacuadra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.